Use of preventive measures and serological screening tools for Leishmania infantum infection in dogs from Europe

Abstract

Background There are several screening tools for detecting Leishmania infantum infection in dogs and various preventive measures to protect against it. Some studies have investigated them, but not many have described their current use. The aim of this study was to investigate which preventive measures and serological screening tools for L. infantum infection were employed from 2012 to 2018 in dogs from different endemic European countries. Methods A set of electronic datasheets was completed for each dog from several veterinary centres. Classification of preventive measures included: (1) repellents, (2) vaccines and (3) immunomodulators. Classification of serological tests included the: (1) direct agglutination test (DAT), (2) enzyme-linked immunosorbent assay (ELISA), (3) indirect immunofluorescence (IFI), (4) rapid tests and (5) other assays. Dogs were also classified depending on their risk of exposure and living area. Results Information from 3762 dogs was gathered. Preventive measures were applied in 91.5% of dogs and the most frequently used were repellents (86.2%) followed by vaccines (39.8%) and Leisguard® (15.3%). The different types of repellents (collar and spot-on) were used similarly. A combination of a vaccine and repellents was preferred in the high-risk group while the low-risk preferred a combination of Leisguard® and a repellent (Chi-square test: X2 = 88.41, df = 10, P < 0.001). Furthermore, all preventive measures were similarly used through the years except for repellents, which were predicted to have a small increase of use each year. Regarding serological screening tools, the most used were rapid and ELISA tests. Rapid tests, ELISA tests and DAT were used similarly through the years, but a significant change was found in the use of IFI and other assays whose use decreased a little each year. Conclusions Repellents were the preferred measure, while vaccines and Leisguard® were second-line options. Some dogs were not treated by any measures, which highlights the need for dog owner education. Moreover, there seems to be a preference for rapid tests in the clinical setting to detect specific L. infantum antibodies while ELISA or IFI are less often employed. This underlines an increasing problem, as qualitative rapid tests have a variable diagnostic performance limiting the adequate diagnosis of seropositive dogs in endemic areas. Graphical abstract

Establishment of an indicator framework for the transmission risk of the mountain-type zoonotic visceral leishmaniasis based on the Delphi-entropy weight method

“…The biological activity and size of the sandfly population, as well as that of latent dogs contribute substantially to the dissemination of disease [ 17 ]. Regarding biological factors, individual factors, such as the use of bed nets and repellents were considered as influencing factors in several studies [ 18 – 20 ]. However, most studies failed to apply a theoretical and comprehensive framework to identify the specific factors that have the greatest impact on the transmission cycle.…”

Seroprevalence and Risk Factors Associated with Leishmania Infection in Dogs from Portugal

“…This may be explained with the lack of compliance by owners when applying the preventive products on their dogs. In a recent study based on an online questionnaire sent to veterinary clinics in Europe analyzing strategies for preventing L. infantum infection or clinical disease in dogs, it was shown that repellents (86.2%), vaccination (39.8%) and Leishguard ® (15.3%) were the most frequently employed [46].…”

New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine

“…A field study showed its effectiveness in preventing clinical signs, reporting that it offered 68.4% and 92.7% vaccine protection [ 44 ]. However, CaniLeish ® has been off the market since 2021 [ 45 , 46 ]. The LetiFend ® (Laboratorios LETI, Barcelona, Spain) vaccine is a more recent vaccine, and unlike the others, it is the only commercial vaccine composed of a chimeric protein containing five antigenic fragments of four L. infantum proteins (histone H2A and ribosomal proteins LiP2a, LiP2b, and LiP0), with 72% efficiency [ 44 ].…”